Juan Pablo Aparco Balboa

Dr. Juan Pablo Aparco Balboa


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025
Verified
Book Chapter
Closed access
PDF file
VHVioleta Magdalena Rojas Huayta
Violeta Magdalena Rojas Huayta
RGRocio Galvez-Davila
Rocio Galvez-Davila
AHAna Maria Higa-Yamashiro
Ana Maria Higa-Yamashiro
HHHally Ruth Huillca-Maldonado
Hally Ruth Huillca-Maldonado
JBJuan Pablo Aparco Balboa
Juan Pablo Aparco Balboa
SESissy Liliana Espinoza-Bernardo
Sissy Liliana Espinoza-Bernardo

19 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TUTalía Urbina-Valladolid
Talía Urbina-Valladolid
Jhon Alex Zeladita-HuamanJhon Alex Zeladita-Huaman
Jhon Alex Zeladita-Huaman
JBJuan Pablo Aparco Balboa
Juan Pablo Aparco Balboa
PCPaula Méndez Celis
Paula Méndez Celis
LSLaryn Smith
Laryn Smith
SGSonia Celedonia Huyhua Gutierrez
Sonia Celedonia Huyhua Gutierrez
Chemotherapy is essential in the treatment of cancer, but its adverse effects affect quality of life and pharmacological therapy is insufficient to control it. Evidence of non-pharmacological interventions is limited and heterogeneous, requiring rigorous syn-theses. Objective: To systematically review the effect of complementary and alternative medicine (CAM) in managing side effects in adults with cancer undergoing chemothera-py. Methods: Following JBI and PRISMA 2020 guidelines, we searched PubMed, Scopus, Web of Science, and LILACS for clinical trials (2015–2025) evaluating bio-based, mind-body, and energy therapies in cancer patients aged 20–74. Quantitative data were meta-analyzed using DerSimonian–Laird random-effects models in Review Manager to calculate Hedges' g. Results: Of 1109 identified studies, 42 met the inclusion criteria and 26 provided data for meta-analysis. CAM significantly improved sleep quality (8 studies, n = 712, g = 1.008, p = 0.0002, I²: 90.9%) and cancer-related fatigue (9 studies, n = 752, g = 0.659, p < 0.0001, I²=72.7%), and significantly reduced nausea/vomiting (13 studies, n = 989, g = 2.099, p < 0.0001, I²=97.7%,). Sensitivity analyses confirmed these findings were stable and robust against high-risk-of-bias studies. Conclusions: The findings suggest the studies are predominantly in Asian populations and in people with breast cancer and the use of CAM shows a potential benefit as an adjunct intervention to conventional treat-ment in reducing secondary symptoms of chemotherapy, although the marked heteroge-neity suggests caution in their interpretation. Greater standardization of intervention protocols is required to strengthen the certainty of evidence in oncology nursing practice.